Get a Quote

RIPRETINIB
CAS NO.: 1442472-39-0
Chemical Formula: C24H21BrFN5O2
Molecular Weight: 510.4000
DMF&GMP status: Please contact us for more details.
Description:
Ripretinib is an orally bioavailable switch pocket control inhibitor of wild-type and mutated forms of the tumor-associated antigens (TAA) mast/stem cell factor receptor (SCFR) KIT and platelet-derived growth factor receptor alpha (PDGFR-alpha; PDGFRa), with potential antineoplastic activity. Upon oral administration, ripretinib targets and binds to both wild-type and mutant forms of KIT and PDGFRa specifically at their switch pocket binding sites, thereby preventing the switch from inactive to active conformations of these kinases and inactivating their wild-type and mutant forms. This abrogates KIT/PDGFRa-mediated tumor cell signaling and prevents proliferation in KIT/PDGFRa-driven cancers. DCC-2618 also inhibits several other kinases, including vascular endothelial growth factor receptor type 2 (VEGFR2; KDR), angiopoietin-1 receptor (TIE2; TEK), PDGFR-beta and macrophage colony-stimulating factor 1 receptor (FMS; CSF1R), thereby further inhibiting tumor cell growth. KIT and PDGFRa are tyrosine kinase receptors that are upregulated or mutated in a variety of cancer cell types; mutated forms play a key role in the regulation of tumor cell proliferation and resistance to chemotherapy.

Ripretinib is a kinase inhibitor used for the treatment of advanced gastrointestinal stromal tumor (GIST) that has not adequately responded to other kinase inhibitors such as [sunitinib] and [imatinib]. Ripretinib, also known as Qinlock, is manufactured by Deciphera Pharmaceuticals and was initially approved by the FDA on May 15, 2020. It is the first drug approved as a fourth-line therapy in the specific setting of prior treatment with a minimum of 3 other kinase inhibitors.

**The products protected by patents in this product catalog are used for laboratory analysis, research and development, and cannot be sold to any country or region with patent protection and for commercial purpose. If the resulting patent infringement risks and responsibilities will be borne by the buyer.
Approvals
Active Ingredient Dosage Form; Route Strength Proprietary Name Applicant
RIPRETINIBTABLET;ORAL50MGQINLOCKDECIPHERA PHARMACEUTICALS LLC
Patent Data
Patent No. Patent Expiration Drug Substance Claim Drug Product Claim Patent Use Code
818811307/27/2030DSDP
846117906/07/2032DSDP
894075606/07/2032U-2829
Exclusive Data
Exclusivity Code Exclusivity Expiration
NCE 05/15/2025
ODE-298 05/15/2027